Dale Shepard is an Oncology physician affiliated with Cleveland Clinic. OpenAlex indexes 120 publications with 2,319 citations (h-index 23); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
9500 Euclid Ave
R35
Cleveland, OH 441950001
Telephone
216-444-2451Registry record last updated 27 May 2009.
Clinical trials
- Cabazitaxel in Men 75 Years of Age or Older With Castration-Resistant Prostate Cancer
Sponsor: Case Comprehensive Cancer Center
- Hsp90 Inhibitor AUY922 in Treating Older Patients With Advanced Solid Malignancies
Sponsor: Dale Shepard, MD, PhD
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
16 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- SpringWorks Therapeutics, Inc.Program year202528 payments$33,569openpaymentsdata.cms.gov ↗
- Ipsen Biopharmaceuticals, IncProgram year20256 payments
- Aadi Bioscience, Inc.Program year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
91.5%Kinase inhibitor79.4%Imatinib Mesylate36%Ibrance27%Pazopanib Hcl22%Qinlock15%Part D<11 patientsGamma Secretase Inhibitor12.1%Ogsiveo100%Part D<11 patientsMetabolism & gastrointestinal
8.5%Serotonin-3 Receptor Antagonist8.5%Ondansetron Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Phase 1 Study of Rezatapopt, a p53 Reactivator, in <i>TP53</i> Y220C–Mutated Tumors
New England Journal of Medicine
2026 - Stereotactic Body Radiation Therapy for Sarcoma Pulmonary Metastases
American Journal of Clinical Oncology
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Samir Kapadia, MD
Cleveland Clinic
Lars Svensson, MD
Cleveland Clinic
Mina Chung, MD
Cleveland Clinic
Gene Barnett, MD
Cleveland Clinic
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”